BR9608835A - Processo para reduzir a hiperglicemia e estabilizar o nìvel de glicose no soro em humanos, tripicolinato crÈmico sintético em forma de dosagem unitária, e, uso do mesmo. - Google Patents

Processo para reduzir a hiperglicemia e estabilizar o nìvel de glicose no soro em humanos, tripicolinato crÈmico sintético em forma de dosagem unitária, e, uso do mesmo.

Info

Publication number
BR9608835A
BR9608835A BR9608835-4A BR9608835A BR9608835A BR 9608835 A BR9608835 A BR 9608835A BR 9608835 A BR9608835 A BR 9608835A BR 9608835 A BR9608835 A BR 9608835A
Authority
BR
Brazil
Prior art keywords
stabilize
humans
serum
level
glucose
Prior art date
Application number
BR9608835-4A
Other languages
English (en)
Inventor
Mark F Mccarty
Original Assignee
Nutrition 21
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrition 21 filed Critical Nutrition 21
Publication of BR9608835A publication Critical patent/BR9608835A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"PROCESSO PARA REDUZIR A HIPERGLICEMIA E ESTABILIZAR O NìVEL DE GLICOSE NO SORO EM HUMANOS, TRIPICOLINATO CRÈMICO SINTéTICO EM FORMA DE DOSAGEM UNITáRIA, E, USO DO MESMO"<D>. Processo para estabilizar os níveis de glicose no sangue e reduzir a hiperglicemia associada com diabete tipo II. O tripicolinato crómico sintético é administrado ou oralmente ou parenteralmente a um humano em necessidade do mesmo, a uma dosagem de entre cerca de 1.000 a 10.000 microgramas por dia.
BR9608835-4A 1995-05-12 1996-05-08 Processo para reduzir a hiperglicemia e estabilizar o nìvel de glicose no soro em humanos, tripicolinato crÈmico sintético em forma de dosagem unitária, e, uso do mesmo. BR9608835A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/440,362 US6329361B1 (en) 1995-05-12 1995-05-12 High-dose chromic picolinate treatment of type II diabetes
PCT/US1996/006493 WO1996035421A1 (en) 1995-05-12 1996-05-08 High-dose chromic tripicolinate for the treatment of type ii diabetes

Publications (1)

Publication Number Publication Date
BR9608835A true BR9608835A (pt) 1999-12-07

Family

ID=23748461

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9608835-4A BR9608835A (pt) 1995-05-12 1996-05-08 Processo para reduzir a hiperglicemia e estabilizar o nìvel de glicose no soro em humanos, tripicolinato crÈmico sintético em forma de dosagem unitária, e, uso do mesmo.

Country Status (15)

Country Link
US (1) US6329361B1 (pt)
EP (1) EP0825861B1 (pt)
JP (1) JP3699124B2 (pt)
AR (1) AR004486A1 (pt)
AT (1) ATE227127T1 (pt)
AU (1) AU5733796A (pt)
BR (1) BR9608835A (pt)
DE (1) DE69624699T2 (pt)
DK (1) DK0825861T3 (pt)
ES (1) ES2183952T3 (pt)
IL (1) IL118222A (pt)
PT (1) PT825861E (pt)
RU (1) RU2195934C2 (pt)
WO (1) WO1996035421A1 (pt)
ZA (1) ZA963735B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962030A (en) 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
IL134163A0 (en) * 1997-08-08 2001-04-30 Nutrition 21 Chromium/biotin treatment of type ii diabetes
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
EP0925790A1 (en) * 1997-12-17 1999-06-30 Kartar Dr. Lalvani Vitamin and mineral combinations for the treatment of syndrome X and non-insulin dependent diabetes (NIDDM)
US5932258A (en) * 1998-04-06 1999-08-03 The Iams Company Composition and process for improving glucose metabolism in companion animals
US5948772A (en) * 1998-08-28 1999-09-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US6143301A (en) 1998-08-28 2000-11-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US5905075A (en) * 1998-08-28 1999-05-18 Ambi Inc. Chromium nicotinate compositions and uses thereof
AU6044699A (en) 1998-09-17 2000-04-03 Akesis Pharmaceuticals, Inc. Compositions and methods for treatment of glucose metabolism disorders
US6376549B1 (en) 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
ES2223924T3 (es) 2000-09-21 2005-03-01 Nutrition 21, Inc. Composiciones que contienen cromo para el tratamiento de la diabetes, la reduccion de la grasa corporal, la mejora de la sensibilidad a la insulina, la reduccion de la hiperglicemia y la reduccion de la hipercolesteremia.
WO2003090671A2 (en) * 2002-04-23 2003-11-06 Nutrition 21, Inc. Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
CN100457122C (zh) * 2002-05-14 2009-02-04 尼普洛株式会社 包含三价铬离子的化合物在制备用于预防和/或治疗淀粉样变性的药物的应用
US6831077B2 (en) * 2002-07-25 2004-12-14 Comprehensive Neuroscience, Inc. Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation
US20050019435A1 (en) * 2003-07-21 2005-01-27 Jeffrey Young Method of treating non-insulin dependent diabetes mellitus and related complications
US20050085454A1 (en) * 2003-10-16 2005-04-21 Natreon Inc. Phenolic antioxidant-chromium complexes for treatment or prevention of type 2 diabetes or glucose intolerance
CA2931881C (en) * 2007-01-31 2018-12-11 Nutrition 21, Inc. Use of chromium histidinate for treatment of cardiometabolic disorders
EP3050568B1 (en) 2007-03-13 2020-12-02 JDS Therapeutics, LLC Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
PL2448412T3 (pl) 2009-07-01 2019-11-29 Jds Therapeutics Llc Kompleksy chromu jako środki podnoszące poziom transporterów glukozy w mózgu
US8933022B2 (en) 2011-03-01 2015-01-13 Jds Therapeutics, Llc Methods and compositions for the treatment and prevention Hypoglycemia and related disorders
EP3256004A1 (en) 2015-02-13 2017-12-20 Mars, Incorporated Pet food feeding system
MX2018009748A (es) 2016-02-11 2019-02-07 Nutrition 21 Llc Composiciones que contienen cromo para mejorar la salud y el estado físico.
US10820617B1 (en) 2018-03-29 2020-11-03 Government Of The United States, As Represented By The Secretary Of The Air Force All inclusive electrolytes, vitamins, and protein powder training supplement

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315927A (en) * 1980-08-08 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Dietary supplementation with essential metal picolinates
US5087623A (en) * 1988-05-31 1992-02-11 Nitrition 21 Chromic picolinate treatment
US5164384A (en) 1991-06-19 1992-11-17 Metagenics, Inc. Anabolic mineral formula

Also Published As

Publication number Publication date
MX9708628A (es) 1998-06-28
IL118222A (en) 2000-06-01
US6329361B1 (en) 2001-12-11
ATE227127T1 (de) 2002-11-15
AR004486A1 (es) 1998-12-16
ZA963735B (en) 1997-01-09
JP3699124B2 (ja) 2005-09-28
WO1996035421A1 (en) 1996-11-14
DK0825861T3 (da) 2003-03-03
DE69624699D1 (de) 2002-12-12
EP0825861A1 (en) 1998-03-04
AU5733796A (en) 1996-11-29
RU2195934C2 (ru) 2003-01-10
JPH11504941A (ja) 1999-05-11
ES2183952T3 (es) 2003-04-01
DE69624699T2 (de) 2003-03-20
IL118222A0 (en) 1996-09-12
EP0825861B1 (en) 2002-11-06
PT825861E (pt) 2003-03-31

Similar Documents

Publication Publication Date Title
BR9608835A (pt) Processo para reduzir a hiperglicemia e estabilizar o nìvel de glicose no soro em humanos, tripicolinato crÈmico sintético em forma de dosagem unitária, e, uso do mesmo.
BR9810378A (pt) Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
KR960700059A (ko) 파킨슨씨 병 및 파킨슨 중후군의 치료에 카르바마제핀 및 옥스카르바제핀의 이용(application of carbamazepine and oxcarbazepine in the treatment of parkinson&#39;s disease and parkinsonian syndromes)
DK642587D0 (da) Insulinpraeparat
BR9812102A (pt) Composições terapêuticas e dietéticas, contendo ácidos graxos essenciais e dissulfetos bioativos
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
BR9909705A (pt) Recipiente para alimentos com múltiplas camadas
BR9708632A (pt) Composto calcilìticos
FR2699077B1 (fr) Application d&#39;anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
BR0312947A (pt) terapias para insuficiência renal empregando-se interferon-beta
BR0010593A (pt) Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv
BR9712816A (pt) Derivados de benzamidina e seu uso como medicamentos com uma atividade antagonista ltb4
SE9201573D0 (sv) Use of igf-1
BR9807112A (pt) Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato
EE03420B1 (et) Farmatseutiline kompositsioon maania ja bipolaarse häire raviks
FR2836336B1 (fr) Utilisation dans un traitement cosmetique d&#39;une fraction phenolique riche en dihydrochalcones
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
BR9908716A (pt) Tratamento de disfunção sexual em certos grupos de pacientes
BR9813114A (pt) Uso de antagonistas tnf para produzir medicamentos, pacote comercial, e, processo para estabelecer se um paciente que esteja sofrendo de sépsis deva ser tratado com os antagonistas tnf
BR9810142A (pt) Tratamento de diabete com tiazolidinadiona e sulfonil-uréia
BR9910185A (pt) Uso de um composto, e, processo para o tratamento de um paciente que sofre de, ou em risco de, uma doença micobacteriana
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.
BR9703451C1 (pt) Composto natural para o tratamento de diabete ecâncer etc
Dickstein et al. Triamterene calculus
DE69310721D1 (de) Zuckerderivate von makroliden

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: SUGIRO O INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NO ART. 25 DA LEI 9279 DE 14/05/96.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: ARQUIVAMENTO DEFINITIVO

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2295 DE 30/12/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ATE A 24A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.